Allopregnanolone, a GABA-A receptor agonist, decreases gonadotropin levels in women. A preliminary study. Isoallopregnanolone is an isomer to allopregnanolone, but without GABA A receptor effects.
Introduction
The pulsatile secretion of follicle-stimulating hormone (FSH) and luteinising hormone (LH) from the pituitary reflects the pulsatile secretion of GnRH (Gonadotropin-Releasing Hormone) from the medial basal hypothalamus. Abnormalities of GnRH secretion, both regarding frequency and amplitude of pulses, are discernible in women with hypogonadotropic hypogonadism [1] . Animal and in vitro studies suggest that the effect is mediated by neuroactive steroids [2] [3] [4] [5] . Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) is an endogenous metabolite from progesterone but also a neuroacive steroid and a potent modulator of the gamma-aminobutyric acid A (GABA A ) receptor [6] . It potentiates the effect of GABA by binding to the GABA A receptor complex, thus enhancing inhibitory neurotransmission. In humans, injections of allopregnanolone cause sedation, objectively measured by a reduced saccadic eye velocity [7] . Isoallopregnanolone (3β-hydroxy-5α-pregnan-20-one) is also a progesterone metabolite and an isomer to allopregnanolone. As far as we know today, isoallopregnanolone lacks hormonal or GABA A receptor effects [8] .
Allopregnanolone and isoallopregnanolone serum concentrations vary during the menstrual cycle and in pregnancy in parallel with progesterone [9] [10] [11] , as a reflection of steroid synthesis in the ovaries [9, 12] . In addition, both steroids are secreted from the adrenal cortex and can be synthesised de novo in the central nervous system from cholesterol [9] . Allopregnanolone secretion from the adrenal cortex increases during stress as shown in both animals and humans [13] [14] .
There are animal studies suggesting regulatory neuroendocrine effects of allopregnanolone via the GABA A receptor. In female rats, ovulation was suppressed by allopregnanolone injections into the cerebral ventricles (icv), evidenced by a decreased number of oocytes collected at estrus. When endogenous allopregnanolone was blocked, the number of oocytes was subsequently increased [15] . In ovariectomised rats, primed with oestrogen and progesterone, LH serum levels decreased following icv allopregnanolone, suggesting involvement of the GABA A receptor and the dopamine system [16] . Barbiturates, also well known GABA A agonists, have been shown to inhibit ovulation in rats through the GABA A receptor [17] .
Inhibition of hypothalamic GnRH secretion is the most common explanation behind anovulation in women of fertile age. However, the condition known as hypothalamic amenorrhea has so far been little understood and diagnosed by exclusion of other causes for anovulation. Although hypothalamic amenorrhea brings about major problems like infertility and osteoporosis, the mechanisms are poorly understood and further studies are warranted.
In the present study, we aimed to investigate if the GABA active steroid allopregnanolone could affect the secretion of FSH, LH, oestradiol and progesterone when administered in the follicular phase in healthy, menstruating women.
Methods

Subjects
Twelve women were included in the allopregnanolone (ALLO) group and seven women in the isoallopregnanolone (ISOALLO) group. The women were recruited to each arm separately through advertisement in the local newspaper. Pharmacokinetics and sedative effects of allopregnanolone have been described previously for the ALLO group [7] , as well as pharmacokinetics and sedative effects of isoallopregnanolone in the ISOALLO group [18] .
Inclusion criteria for both groups were healthy women aged 18-40 with regular menstrual cycles. Exclusion criteria were treatment with any steroid compound (including oral contraceptives and hormonal intrauterine devices) for at least six months prior to enrolment in the study, treatment with benzodiazepines or other psychotropic drugs within the last three months, and treatment with any daily over-the-counter drug during the last four weeks prior to inclusion. Further exclusion criteria were any current or previous significant somatic disease, any mental disorder, including premenstrual dysphoric disorder, during the last six months, or a history of drug abuse or excessive alcohol use (more than six glasses of wine or beer during one day within the last four weeks). The presence of psychiatric disorders at inclusion was evaluated using a structured psychiatric interview, Primary Care Evaluation of Mental Disorders (PRIME-MD). Prior to inclusion, a physical and gynaecological examination was performed, as well as a routine blood chemistry screen (total blood cell count, plasma glucose, liver enzymes, creatinine, sodium and potassium). All subjects had negative pregnancy tests and normal blood chemistry screens. No night work or jet-lag travels were allowed during the week preceding the study day. The women were informed in detail, both orally and in writing, about the purpose and performance of the study and gave their oral and written informed consent prior to inclusion. The study procedures were in accordance with ethical standards for 
Experimental substances
The Umeå University Hospital Pharmacy prepared both the allopregnanolone and isoallopregnanolone experimental substances. The allopregnanolone solution for intravenous administration was formulated with purified allopregnanolone (3α-hydroxy-5α-pregnan-20-one, Umecrine AB, Umeå, Sweden), 15 mg dissolved in 100 ml albumin solution (Albumin, 200 mg/ml) using an ultrasound bath. The final solution contained 0.126 ± 0.003 mg/ml (mean ± SEM) allopregnanolone (n = 9). The isoallopregnanolone solution for intravenous administration was formulated with purified isoallopregnanolone (3β-hydroxy-5α-pregnan-20-one, Umecrine AB, Umeå, Sweden), 8 mg dissolved in 100 ml albumin solution (Albumin, 200 mg/ml) using an ultrasound bath. The solution was then filtered through two sterile filters. The final solution contained 0.0736 ± 0.00807 mg/ml (mean ± SD) isoallopregnanolone (n = 6). Concentrations of allopregnanolone and isoallopregnanolone, in each batch, were determined using high performance liquid chromatography (HPLC) and UV absorbance, respectively, as described earlier [19] .
Study protocol
Administration of allopregnanolone or isoallopregnanolone was performed in the follicular phase in both study groups. In the ALLO group, the experiment was performed on cycle day 5-10, and in the ISOALLO group, on cycle day 6-12. To avoid influence of diurnal variations, all study patients were tested during the same time of the day with the first injection at 08.30 AM. No subjects had consumed alcohol during 24 hours prior to testing. Caffeine and tobacco use was restricted throughout the study day. Prior to the experiment, an intravenous cannula was inserted in each forearm, one for administration of the experimental substance, and one for drawing blood samples.
In the ALLO group, baseline serum levels of allopregnanolone, FSH, LH, progesterone and estradiol were drawn 15 minutes before the first allopregnanolone injection. Three intravenous injections of allopregnanolone were given with 30-minute intervals, using doses of 0.015, 0.03 and 0.045 mg/kg, producing a cumulative dose of 0.09 mg/kg. The reason for repeated dosing was that in this study, allopregnanolon was given for the first time to humans. This cumulative dose produced a sedative effect measured by a reduced saccadic eye movement, confirming that the dose affected the GABA-system [7] . Each injection was given over 30 seconds. After the first allopregnanolone injection, blood samples for serum concentrations of allopregnanolone, FSH, LH, progesterone and oestradiol were drawn at 5, In the ISOALLO group, baseline serum levels of isoallopregnanolone, allopregnanolone, FSH, LH, progesterone and oestradiol were drawn 5 min before the first isoallopregnanolone injection. Three intravenous injections of isoallopregnanolone were given with 30-minute intervals, using doses of 0.04, 0.06 and 0.10 mg/kg, producing a cumulative dose of 0.20 mg/kg. The reason for repeated dosing was that in this study, isoallopregnanolon was given for the first time to humans. This cumulative dose did not affect the GABA-system as confirmed with saccadic eye movement measurements [18] . Each injection was given with an infusion rate of 2 mg/min. Extraction and separation of cross reacting steroids All samples were extracted with diethyl ether. Plasma (0.4 ml) was pipetted into a cylindrical flat bottom glass vial, where after water (0.5 ml) and diethyl ether (3.0 ml) were added. The samples were then allowed to stand on an orbital shaker for ten minutes. Following the liquidliquid extraction, the water phase was frozen, and the ether phase was decanted and evaporated under nitrogen. In the ALLO group, allopregnanolone was separated from cross reacting steroids with celite chromatography. The method has been described in detail earlier [7] . In the ISOALLO group, separation of allopregnanolone and isoallopregnanolone from cross reacting steroids was made with HPLC, and in addition, allopregnanolone was eluted from the HPLC. The fractions were symmetrically collected around the peak retention time for isoallopregnanolone or allopregnanolone for further analysis with radioimmunoassay (RIA). No cross-reacting steroids had retention times close to the collected fractions. The recovery of the extraction and HPLC procedure was for isoallopregnanolone 95%. The recovery of allopregnanolone was 98% and the results were compensated for recovery. The method has been described in detail earlier [18] .
Radioimmunoassays of allopregnanolone and isoallopregnanolone
Allopregnanolone was measured by RIA using a polyclonal rabbit antiserum raised against 3α-hydroxy-20-oxo-5α-pregnan-11-yl carboxymethyl ether coupled to bovine serum albumin, made by R. H. Purdy, (The Scripps Research Institute, La Jolla, CA, USA; 20). The method has been described in detail earlier [7] .The sensitivity of the assay was 25 pg with an intra-assay coefficient of variation for allopregnanolone of 6.5% and an inter-assay coefficient of variation of 8.5%. For the isoallopregnanolone (3β-hydroxy-5α-pregnan-20-one) analysis, an antibody against pregnenolone (pregnenolone-3-monohemisuccinate-HSA; ICN Pharmaceuticals, Inc Orangeburg, NY, USA) was used as it also binds to isoallopregnanolone. Cross-reactivity with isoallopregnanolone was 26.6%, allopregnanolone 13%, 5α-pregnan-3,20-dione 7%, 5β-pregnane-3β-ol-20-one <1%, 5β-pregnan-3α-ol-20-one <1%, 5α-pregnan-3α,20α-diol <1%, pregnenolone 100%. The sensitivity of the assay (2 SD above the blank mean) was 0.11 pmol or 35.8 pg, with an intra-assay coefficient of variation of 8.5% and an inter-assay coefficient of variation of 10.7%. The method has been described in detail earlier [18] . 
Results
Demographic data of the study groups are presented in Table I . Out of twelve included subjects, ten women completed the allopregnanolone (ALLO) study; two never performed the experiment because of changes of residency. Out of seven included subjects, five women completed the isoallopregnanolone (ISOALLO) study. Of the two drop-outs, one was excluded because of a vasovagal reaction on the test day at insertion of the cannulas and was never given any test injection. The second one was excluded to avoid interference with the preovulatory LH peak which was ongoing at the planned test day. The serum concentrations of allopregnanolone for one woman in the ALLO group were missing at 150, 600 and 780 minutes. In the ISOALLO group there were missing values for serum concentrations of allopregnanolone for one woman at 5 and 88 minutes, and for another woman at 150 minutes.
Missing values for serum concentrations of isoallopregnanolone in the ISOALLO group were for one woman at 105 minutes, for another woman at 330 and 600 minutes, and for a third woman at 330 minutes. 
Discussion
The main finding of the present study is that allopregnanolone, a GABA A -active steroid, decreases the serum levels of FSH and LH when given as intravenous injections in the follicular phase. In addition, the negative correlation noted between allopregnanolone and FSH levels points to the possibility of a direct mechanism.
However, there are several limitations to our study. Firstly, the number of participants was small. Secondly, the two groups were recruited and tested at different occasions. Thirdly, the concentrations of allopregnanolone were supra-physiological. The possible consequences of the methodologically limitations to our study will be further discussed below.
There was a slight difference in baseline levels of oestradiol and FSH between the two groups. A plausible explanation to the higher baseline levels of oestradiol in the ISOALLO group is that they had higher body mass index. Forty percent of the subjects in the ALLO group were tobacco smokers but none in the ISOALLO group. Whether this fact influenced the hormone levels and/or metabolism is not clear. Other factors that could possibly interfere with baseline concentrations of oestradiol or FSH, e.g. age, menstrual cycle length and actual cycle day at injection, were not significantly different between the two groups.
An important question is if the effect seen here with supraphysiological concentrations of allopregnanolone could be applied to the physiological situation. The decrease in gonadotropins in the ALLO group was present 5 minutes after the first injection of allopregnanolone, when serum levels of allopregnanolone were approximately 20 nmol/l.
Mean physiological levels of allopregnanolone in healthy women are 0.3-1.9 nmol/l in the follicular phase and 2.1-3.7 nmol/l in the luteal phase [10, [21] [22] . In humans suffering from acute stress, endogenous allopregnanolone levels have been shown to rise from 1.0 to1.3 nmol/l and the change was statistically significant [14] . Although the increase is discrete, the time point in relation to menstrual cycle phase as well as if the rise is constant or not might be of importance for effects on the ovulatory mechanism. The highest physiological allopregnanolone levels are reached in late pregnancy when maternal mean levels in plasma are 45-75 nmol/l with an inter-individual variation between 20 and more than 150 nmol/l [11, 23] . Still, as the changes in gonadotropin levels were detectable at the first time point after injection and effects of lower concentrations between baseline and the 5 minute value remain unstudied, an effect on gonadotropin levels of allopregnanolone in the physiological interval can not be excluded.
The results presented here are in accordance with earlier in vitro and animal studies where GnRH secretion, decreased gonadotropin levels and suppression of ovulation have been noted following allopregnanolone administration [2] [3] [4] [15] [16] . In addition, other GABA A agonists have been found to inhibit ovulation in rats [17] , however not in primates [24] . Several of the above mentioned studies displayed no effect of isoallopregnanolone on neuroendocrine function and it was thus concluded that the allopregnanolone effect is an exclusive GABA A receptor mediated mechanism [2] [3] [4] . A limited number of studies have shown absence of, or opposite effects of allopregnanolone on neuroendocrine function in vitro and in vivo [25] [26] [27] [28] .
One explanation for these discrepancies might be that the sub-composition of the GABA A receptor is different during different endocrine conditions [29] [30] . Another plausible explanation is that the effect of allopregnanolone displays a bimodal pattern under certain circumstances [31] .
There is a limited body of evidence indicating a relationship between levels of endogenous allopregnanolone and anovulation in humans. Higher baseline serum levels of allopregnanolone have been reported in subjects suffering from hypothalamic amenorrhea compared to healthy controls in the follicular phase of the menstrual cycle [32] . Moreover, elevated serum levels of allopregnanolone were found in patients with premature ovarian failure compared to both postmenopausal and fertile women [33] . Apart from pregnancy, the only other situation were elevated levels of allopregnanolone have been noted in humans is during stress [14] .
As expected, both concentrations of allopregnanolone in the ALLO group and concentrations of isoallopregnanolone in the ISOALLO group increased in a dose-dependent manner following the injections. However, in parallel with the rise in isoallopregnanolone levels in the ISOALLO group there was a slightly delayed increase in allopregnanolone levels. In an earlier study, a correlation between allopregnanolone and isoallopregnanolone levels was noted after administration of isoallopregnanolone [18] . The reason for this relationship is probably that a metabolism of isoallopregnanolone into allopregnanolone could occur, a phenomenon observed earlier [34] . The lack of effect on gonadotropins in the ISOALLO group supports the theory that the allopregnanolone decreasing effect on gonadotropin secretion is mediated through a specific GABA A receptor activation and not an unspecific steroidal effect [35] .
In the ALLO group, there was no increase in progesterone or oestradiol levels. Thus, the decrease in FSH and LH was not caused by negative feed-back of progesterone and oestradiol on the hypothalamic-pituitary-gonadal axis. In the ISOALLO group, on the other hand, there was an increase in progesterone levels starting at 35 min, a finding that is difficult to interpret. This increase of progesterone was however modest and did obviously not affect the gonadotropin levels. Nevertheless, the result is in accordance with an earlier study where pregnanolone (an isomer to allopregnanolone with similar but less potent effects on the GABA A receptor) injections were given to women in the follicular phase and an increase in progesterone levels was found but no effect on gonadotropin secretion or oestradiol levels [36] .
In conclusion, the present study shows that allopregnanolone reduces serum levels of FSH and LH in healthy women in the follicular phase, but does not influence serum concentrations of oestradiol and progesterone. Isoallopregnanolone did not affect levels of gonadotropins, indicating that the effect is mediated via the GABA A receptor. Whether the decreased levels of gonadotropins are due to inhibited synthesis, decreased secretion, altered pulsatility or increased metabolism is unclear. Further studies are warranted to explore if a physiological rise in allopregnanolone, for instance in response to stress, could interfere with gonadotropin effects on the pituitary, and ultimately reproductive function in women. 
